Dr. Barbara Lueckel
Roche Pharma Partnering, Global Head of Research Technologies
Barbara Lückel is the Global Head of Research Technologies Partnering and a member of the Roche Pharma Partnering leadership team since May 2019. In her role she is working closely with the two research and early development organizations at Genentech and Roche (gRED and pRED) to identify transformative science developed by biotechs around the globe and is responsible for setting up partnerships with such biotechs to enable discovery programs for novel medicines making a difference for patients’ lives.
Before that, Barbara was a Global Business Development Director in the Innovation Partnering group in Roche Partnering, where she was responsible for the evaluation, negotiation and ultimately alliance management of multiple discovery partnerships for pRED covering different therapeutic modalities in various disease areas.
Barbara joined Roche in 2007 as a Global Drug Delivery Evaluator in Formulation Research, setting up numerous evaluation agreements with biotechs to apply drug delivery approaches to Roche’s pipeline molecules, before fully transitioning to Roche Partnering in 2012.
Prior to Roche, Barbara worked at Novartis for ten years both on formulation development of poorly soluble molecules as well as on evaluations of reformulation opportunities as potential line extensions based on external drug delivery technologies. She is trained as a pharmacist with a PhD from the University of Basel.
Before that, Barbara was a Global Business Development Director in the Innovation Partnering group in Roche Partnering, where she was responsible for the evaluation, negotiation and ultimately alliance management of multiple discovery partnerships for pRED covering different therapeutic modalities in various disease areas.
Barbara joined Roche in 2007 as a Global Drug Delivery Evaluator in Formulation Research, setting up numerous evaluation agreements with biotechs to apply drug delivery approaches to Roche’s pipeline molecules, before fully transitioning to Roche Partnering in 2012.
Prior to Roche, Barbara worked at Novartis for ten years both on formulation development of poorly soluble molecules as well as on evaluations of reformulation opportunities as potential line extensions based on external drug delivery technologies. She is trained as a pharmacist with a PhD from the University of Basel.
